A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction

National Taiwan University Hospital64 enrolled

Overview

Post surgical pain associated with ligament reconstruction may persist for few days after the surgical procedure. Arcoxia is a new anti-inflammatory and analgesic drug that alleviate pain through oral administration. This study will test the safety and efficacy of Arcoxia in the management of post-operational pain in patients receive the ligament reconstruction surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Post-operational Pain

Interventions

Arcoxia(etoricoxib 90 mg/tablet)DRUG

Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days

Eligibility

Sex: ALLMin age: 16 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Men and women age ranged from 16\~35 who have anterior cruciate ligament injury and/or associated injuries are scheduled for ACL reconstruction surgery. 2. Patient agrees to participate into this study and is willing to sign the patient informed consent form.

Locations (1)

National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

Pain at rest at different timepoint after surgical procedures

Time frame: From baseline(preoperation) to 3 days after

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.